Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 2
1992 4
1993 3
1994 2
1995 6
1996 3
1997 4
1998 2
1999 4
2000 4
2001 9
2002 7
2003 7
2004 9
2005 6
2006 7
2007 6
2008 11
2009 5
2010 6
2011 10
2012 10
2013 8
2014 10
2015 15
2016 12
2017 14
2018 12
2019 10
2020 9
2021 13
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
Navarro VJ, Belle SH, D'Amato M, Adfhal N, Brunt EM, Fried MW, Reddy KR, Wahed AS, Harrison S; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Navarro VJ, et al. Among authors: fried mw. PLoS One. 2019 Sep 19;14(9):e0221683. doi: 10.1371/journal.pone.0221683. eCollection 2019. PLoS One. 2019. PMID: 31536511 Free PMC article. Clinical Trial.
Killing Two Birds With No Stone.
Giang J, Harrison DS, Hansen BK, Fried MW, Darling JM. Giang J, et al. Among authors: fried mw. Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):371-374. doi: 10.1002/cld.1064. eCollection 2021 May. Clin Liver Dis (Hoboken). 2021. PMID: 34136144 Free PMC article. Review. No abstract available.
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Sanyal AJ, Munoz B, Cusi K, Barritt AS 4th, Muthiah M, Mospan AR, Reddy KR, Firpi-Morell R, Thuluvath PJ, Bhamidimarri KR, Fried MW; TARGET-NASH Investigators. Sanyal AJ, et al. Among authors: fried mw. Clin Gastroenterol Hepatol. 2023 Oct;21(11):2889-2900.e10. doi: 10.1016/j.cgh.2023.02.024. Epub 2023 Mar 5. Clin Gastroenterol Hepatol. 2023. PMID: 36871772
Reply to Roussel et al.
Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz B, Zink RC, Elliott S, Burleson K, Landis C, Reddy KR, Brown RS. Fried MW, et al. Clin Infect Dis. 2021 Jun 1;72(11):e929. doi: 10.1093/cid/ciaa1621. Clin Infect Dis. 2021. PMID: 33086377 No abstract available.
Barriers to hepatitis C treatment.
McGowan CE, Fried MW. McGowan CE, et al. Among authors: fried mw. Liver Int. 2012 Feb;32 Suppl 1(0 1):151-6. doi: 10.1111/j.1478-3231.2011.02706.x. Liver Int. 2012. PMID: 22212587 Free PMC article. Review.
Real-world evidence in hepatocellular carcinoma.
Mospan AR, Morris HL, Fried MW. Mospan AR, et al. Among authors: fried mw. Liver Int. 2021 Jun;41 Suppl 1:61-67. doi: 10.1111/liv.14864. Liver Int. 2021. PMID: 34155788
Controversies in hepatitis C therapy: Reactivation of hepatitis B virus.
Lieber SR, Fried MW. Lieber SR, et al. Among authors: fried mw. Clin Liver Dis (Hoboken). 2017 Oct 31;10(4):87-92. doi: 10.1002/cld.665. eCollection 2017 Oct. Clin Liver Dis (Hoboken). 2017. PMID: 31186893 Free PMC article. Review. No abstract available.
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
Terrault NA, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA; Hepatitis B Research Network. Terrault NA, et al. Among authors: fried mw. Am J Gastroenterol. 2023 Jul 1;118(7):1214-1225. doi: 10.14309/ajg.0000000000002125. Epub 2022 Dec 23. Am J Gastroenterol. 2023. PMID: 36599136 Clinical Trial.
217 results